Abstract | INTRODUCTION:
Onychomycosis is a fungal infection of the nail apparatus that affects 10 - 30% of the global population. Current therapeutic options for onychomycosis have a low to moderate efficacy and result in a 20 - 25% rate of relapse and reinfection. New therapeutic options are needed to broaden the spectrum of treatment options and improve the efficacy of treatment. AREAS COVERED: This review discusses the emerging pharmacotherapeutics; including topical reformulations of terbinafine, new azole molecules for systemic and topical administration, topical benzoxaboroles and topical polymer barriers. The paper also discusses device-based options, which may be designed to activate a drug or to improve drug delivery, such as photodynamic therapy and iontophoresis; laser device systems have also begun to receive regulatory approval for onychomycosis. EXPERT OPINION:
|
Authors | Aditya K Gupta, Fiona C Simpson |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 13
Issue 8
Pg. 1131-42
(Jun 2012)
ISSN: 1744-7666 [Electronic] England |
PMID | 22533461
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antifungal Agents
- Azoles
- Boron Compounds
- Bridged Bicyclo Compounds, Heterocyclic
- Echinocandins
- Naphthalenes
- Polymers
- Allylamine
- Terbinafine
|
Topics |
- Allylamine
(administration & dosage)
- Antifungal Agents
(administration & dosage)
- Azoles
(administration & dosage)
- Boron Compounds
(administration & dosage)
- Bridged Bicyclo Compounds, Heterocyclic
(administration & dosage)
- Echinocandins
(administration & dosage)
- Humans
- Iontophoresis
- Lasers
- Naphthalenes
(administration & dosage)
- Onychomycosis
(drug therapy)
- Photochemotherapy
- Polymers
(administration & dosage)
- Terbinafine
|